Peroxitech Therapeutics Secures Seed Financing To Advance New Treatment Of Acute Lung Injury
05/12/21, 11:15 AM
Location
philadelphiaRound Type
seed
Peroxitech Therapeutics, Inc., a biopharmaceutical company developing PIP-2 to reverse acute lung injury (ALI) by targeting the cytokine storm cascade process, today announced their launch with a seed investment from Xontogeny, LLC to advance their lead program through completion of IND-enabling work, including pharmacokinetics studies and additional toxicology preclinical trials.
Company Info
Location
philadelphia, pennsylvania, united states
Additional Info
Peroxitech Therapeutics is a biopharmaceutical company focused on treating acute lung injury (ALI) through its development of a novel peptide to target a newly-identified pathway of disease presentation. Their lead compound, PIP-2, works to eliminate the reactive oxygen species (ROS) build up in the lungs that leads to respiratory failure with hypoxemia and tissue acidosis characteristic of acute lung injury, regardless of etiology. For more information, please visit: www.peroxitech.com.